DOACs in cancer-associated thrombosis
Direct oral anticoagulants for venous thromboembolism in people with cancer.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 8, 5, 8, 6, 7.
New guidelines and consensus this year
- [Management of venous thromboembolism in children with acute lymphoblastic leukemia: Recommendations from the harmonization workshops of the Leukemia Committee of the French Society for Childhood Cancer (SFCE)]Bull Cancer2026 Sep 16
- Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement: A Report of the American College of CardiologyJ Am Coll Cardiol2026 Sep 15
All papers from the last 12 months
183 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 StudyAm J Hematol2026 NovPMID 42644221RCT
- Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioningCurr Opin Hematol2026 Nov 1PMID 42348666Review
- Factors Associated With Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated ThrombosisJACC CardioOncol2026 Oct 15PMID 42886105
- Real-World Use and Outcomes of Post-Discharge Venous Thromboembolism Prophylaxis After Thoracic Cancer OperationJ Am Coll Surg2026 Oct 13PMID 42868038
- Predicting drug-drug interaction and optimal dosing regimens of rivaroxaban combined with ceritinib using physiologically based pharmacokinetic and pharmacodynamic modelingEur J Pharmacol2026 Oct 8PMID 42849684
- Fragility Analysis Should Complement Statistical Reporting in Thrombosis Trials: Lessons from Reduced-Dose Direct Oral Anticoagulants for Cancer-Associated Venous ThromboembolismJ Thromb Haemost2026 Oct 3PMID 42829086Review
- A coronary event without coronary artery disease: the hidden role of inherited thrombophilia-a case reportEur Heart J Case Rep2026 OctPMID 42820085
- Beyond Sinus Rhythm: Rhythm Control and Mechanism-Based Secondary Prevention in Atrial Fibrillation-Related StrokeJ Atheroscler Thromb2026 Oct 1PMID 42386605Review
- Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysisDrug Saf2026 OctPMID 42295501Meta-analysisSystematic review
- Real-world evaluation of therapeutic anticoagulation for cancer-associated thromboembolism: A retrospective analysisJ Oncol Pharm Pract2026 OctPMID 40170464
More hematology trends
All specialties →Gene therapy for sickle cell and thalassaemia
CRISPR-based and lentiviral gene therapies for haemoglobin disorders.
CAR-T in blood cancers
Chimeric antigen receptor T-cell therapy in lymphoma, myeloma and leukaemia.
Key point: CAR T-cell therapy has emerged as an effective option for refractory or progressive mantle cell lymphoma after prior covalent BTK inhibitor treatment.
Immune thrombocytopenia
ITP and its newer treatments.
Key point: Adult ITP care incorporates newer thrombopoietin receptor agonists and small molecule kinase inhibitors, emphasizing thrombotic risk and quality of life.
Myelofibrosis treatment
JAK inhibitors and newer drugs in myelofibrosis.
Key point: Ruxolitinib-based combination regimens showed improved spleen and symptom responses with acceptable safety, with efficacy significantly influenced by prior JAK inhibitor exposure.
Post-transplant cyclophosphamide
Cyclophosphamide after stem cell transplant to prevent graft-versus-host disease.
Key point: Post-transplant cyclophosphamide appears to reduce graft-versus-host disease without increasing relapse or mortality in matched related donor transplantation for acute leukemia.
Haemophilia
Haemophilia and its newer treatments, including gene therapy and non-factor drugs.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("cancer-associated thrombosis"[tiab] OR ("venous thromboembolism"[tiab] AND cancer[tiab])) AND (apixaban[tiab] OR rivaroxaban[tiab] OR edoxaban[tiab] OR DOAC*[tiab] OR "direct oral anticoagulant*"[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.